- Home
- EVT vs HRMY Comparison
EVT vs HRMY Comparison
Compare EVT & HRMY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EVT
- HRMY
- Stock Information
- Founded
- EVT 2003
- HRMY 2017
- Country
- EVT United States
- HRMY United States
- Employees
- EVT N/A
- HRMY N/A
- Industry
- EVT Finance Companies
- HRMY Biotechnology: Pharmaceutical Preparations
- Sector
- EVT Finance
- HRMY Health Care
- Exchange
- EVT Nasdaq
- HRMY Nasdaq
- Market Cap
- EVT 1.7B
- HRMY 2.0B
- IPO Year
- EVT N/A
- HRMY 2020
- Fundamental
- Price
- EVT $24.10
- HRMY $31.70
- Analyst Decision
- EVT
- HRMY Strong Buy
- Analyst Count
- EVT 0
- HRMY 9
- Target Price
- EVT N/A
- HRMY $54.22
- AVG Volume (30 Days)
- EVT 115.5K
- HRMY 627.2K
- Earning Date
- EVT 01-01-0001
- HRMY 08-05-2025
- Dividend Yield
- EVT 8.32%
- HRMY N/A
- EPS Growth
- EVT N/A
- HRMY 13.13
- EPS
- EVT 6.63
- HRMY 2.62
- Revenue
- EVT $69,404,302.00
- HRMY $744,852,000.00
- Revenue This Year
- EVT N/A
- HRMY $20.10
- Revenue Next Year
- EVT N/A
- HRMY $18.01
- P/E Ratio
- EVT $3.55
- HRMY $12.13
- Revenue Growth
- EVT N/A
- HRMY 20.62
- 52 Week Low
- EVT $19.20
- HRMY $26.47
- 52 Week High
- EVT $25.83
- HRMY $41.61
- Technical
- Relative Strength Index (RSI)
- EVT 60.98
- HRMY 38.57
- Support Level
- EVT $23.22
- HRMY $31.25
- Resistance Level
- EVT $23.75
- HRMY $32.46
- Average True Range (ATR)
- EVT 0.21
- HRMY 1.00
- MACD
- EVT -0.00
- HRMY -0.37
- Stochastic Oscillator
- EVT 85.08
- HRMY 11.69
About EVT Eaton Vance Tax Advantaged Dividend Income Fund of Beneficial Interest
EATON VANCE TAX ADVANTAGED DIVIDEND INCOME FUND is a diversified, closed-end management investment company. Its objective is to provide a high level of after-tax total return consisting mainly of tax-advantaged dividend income and capital appreciation. The fund pursues its objective by investing in dividend-paying common and preferred stocks. Its portfolio of investments consists of electric utilities, energy equipment and services, food products, health care providers and services, internet software and services, and other areas.
About HRMY Harmony Biosciences Holdings Inc.
Harmony Biosciences Holdings Inc is a commercial-stage pharmaceutical company focused on developing and commercializing therapies for patients living with rare neurological diseases who have unmet medical needs. The company's product WAKIX (pitolisant) is a molecule with a novel mechanism of action specifically designed to increase histamine signaling in the brain by binding to H3 receptors and is used for the treatment of cataplexy in adult patients with narcolepsy. The other drug candidates in its pipeline are Pitolisant, HBS-102 (MCHR1 antagonist), BP1.15205 (orexin-2 receptor agonist), ZYN002 (cannabidiol gel), EPX-100 (clemizole hydrochloride), and EPX-200 (lorcaserin), among others.